PEG-OES Nanofibril–Mesenchymal Stem Cell Composition for Targeted Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Systemic administration of drug-loaded nanoparticles results in indiscriminate diffusion throughout the body, reducing availability at the site of interest, and existing cell therapies for targeted delivery are transient.
Innovation Solution
A nanomaterial-stem cell composition comprising PEG-OES based fibrils incorporated into mesenchymal stem cells, which load and deliver therapeutic molecules like rapamycin, enabling targeted and sustained release at the site of interest.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If drug-loaded nanoparticles are administered systemically, then the therapeutic agents can reach various parts of the body, but the availability at the site of interest is reduced due to indiscriminate diffusion
Solution Approach 1:
The patent uses mesenchymal stem cells as intermediary carriers to transport nanofibril-based drug delivery systems to specific target sites. The stem cells naturally migrate to sites of injury or disease, serving as a biological mediator that directs the therapeutic agents precisely where needed, thereby avoiding indiscriminate systemic diffusion while maintaining high availability at the target site.
Solution Approach 2:
The patent employs a nested structure where drug-loaded nanofibrils are incorporated within mesenchymal stem cells. The nanofibrils (containing the therapeutic agents) are nested inside the stem cells, creating a hierarchical delivery system where the outer stem cell layer provides targeted navigation and the inner nanofibril layer provides controlled drug release at the target site.
2Duration of action of moving object
If cell therapy is used for targeted delivery, then the nanoparticles can be delivered to a particular location, but the therapy is transient and lacks sustained release capability
Solution Approach 1:
The patent achieves continuous and sustained therapeutic action through a dual-layered release mechanism. The mesenchymal stem cells provide prolonged presence at the target site due to their ability to integrate into local tissues and continue functioning. Simultaneously, the nanofibril-based drug carriers within the cells provide controlled, sustained release of therapeutic agents over extended periods, ensuring continuous useful action rather than transient effects.
3Productivity
If nanomaterials are incorporated into stem cells, then targeted and sustained drug delivery is achieved, but the complexity of the composition increases
Solution Approach 1:
The patent employs mesenchymal stem cells as universal carriers that can deliver multiple types of therapeutic agents through the nanofibril system. The stem cells themselves provide multiple functions including targeted migration to injury sites, immunomodulatory effects, and structural support. The nanofibril composition can accommodate various drugs and therapeutic molecules, making the overall system highly versatile and multi-functional, thereby justifying the increased complexity through substantial gains in delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition allows efficient internalization of nanoparticles into stem cells without affecting cell viability, providing sustained and localized drug delivery with enhanced immunoregulatory potency and reduced systemic side effects.
Implementation Method 1
The extremely small size and large surface area of nanoparticles can allow them to readily enter the cells in vitro and in vivo to enhance various molecular changes by delivering drugs, proteins, genes, or imaging agents
Implementation Method 2
The nanoparticles can also provide sustained and localized drug release
Data Source
AI summary
Disclosed herein are biocompatible and biodegradable nanomaterials combined with molecules of interest and stem cells in a variety of stable and safe compositions. The nanomaterials comprise poly(ethylene glycol)-oligo(ethylene sulfide) (PEG-OES) amphiphilic block-copolymers that self-assemble in supramolecular aggregates of fibrillar shape. The fibrillar architecture of the assemblies allows the easy, fast and not harmful internalization into stem cells, including the preferred umbilical cord derived mesenchymal stem cells (UC-MSC). The OES core enables loading of hydrophobic molecules, such as imaging agents and drugs, which are carried by the nFIB into the stem cells for a final product that comprises a composition of MSC, nFIB and therapeutic molecule (e.g., MSC-nFIB-Rapamycin). The technology can be utilized to enhance the immunoregulatory potency of MSC via intracellular nanomaterial delivery of immunosuppressive drugs, and to obtain active site-targeting and localized delivery of drug-loaded nanofibrils by exploiting the MSC homing ability.